Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Where To Buy Pirfenidone"

19:54 EDT 24th April 2014 | BioPortfolio

Matching Channels


Matching News

Inhaled Pirfenidone Shows Promise in Lung Fibrosis

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced additional measured advantages of inha...

InterMune ASCENDs on new Phase III pirfenidone data

Brisbane, California-based InterMune's stock soared 170.8% higher on 25 February to close at $37.80 per share with a $3bn market cap after the company said pirfenidone cut the percentage of IPF patien...

GNI's pirfenidone set for Chinese launch for IPF

GNI Group has overcome one of the main remaining hurdles to the commercialization of its antifibrotic agent pirfenidone (F647) for adult idiopathic pulmonary fibrosis (IPF) in China, receiving an impo...

InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopa...

GNI agrees ex-China pirfenidone deal with AFT

GNI Group has struck a deal with the New Zealand-based company AFT Pharmaceuticals for the commercialization of the idiopathic pulmonary fibrosis drug Etuary (pirfenidone/F647) in a number of selected...

Genoa's Inhaled Pirfenidone Shows Potential in Lung Fibrosis

Genoa Pharmaceuticals and collaborators Martin Kolb and Kjetil Ask at McMaster University announced additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathi...

InterMune's Drug Pirfenidone Delays Lung Disease Progression

In a late-stage trial, InterMune Inc's experimental drug pirfenidone reduced progression of idiopathic pulmonary fibrosis (IPF), which leads to loss of lung function, taking the treatment closer to U....

Esbriet pirfenidone: Phase III data

Matching PubMed Articles

Antifibrotic Effect of Pirfenidone on Human Pterygium Fibroblasts.

Abstract Objective: The effects of pirfenidone were investigated on cultured human pterygium fibroblasts (HPFs). Methods: HPFs were obtained from pterygium surgery and subjected to primary culture. Af...

Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.

Purpose:This study aimed to investigate the effect of pirfenidone on the interleukin (IL)-1β-induced hyaluronic acid (HA) increase in orbital fibroblasts from patients with thyroid-associated ophthal...

Pirfenidone: an update on clinical trial data and insights from everyday practice.

Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonar...

Improved Mitochondrial Function Underlies the Protective Effect of Pirfenidone against Tubulointerstitial Fibrosis in 5/6 Nephrectomized Rats.

Dysfunctional mitochondria participate in the progression of chronic kidney disease (CKD). Pirfenidone is a newly identified anti-fibrotic drug. However, its mechanism remains unclear. Mitochondrial d...

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events.

Pirfenidone is currently the only approved therapy for idiopathic pulmonary fibrosis, following studies demonstrating that treatment reduces the decline in lung function and improves progression-free...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement